The integration of PI3K/AKT inhibitors with alternative treatment modalities, such as immunotherapy, MEK inhibitors, or chemotherapy, represents a promising strategy to improve therapeutic results in NSCLC [149,150,151,152,153]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.